Scavilla confirmed the acquisition of Nevro Corporation for $250 million, expanding Globus Medical's reach into the musculoskeletal market, particularly in neuromodulation technology and chronic ...

The company has taken strategic steps to strengthen its market position, including launching innovative products and acquiring Nevro to expand into the neuromodulation market. Despite these ...

Before that, as Regional Director at Nevro, he doubled division revenue and contributed to the successful U.S. launch of the HF10 therapy.

The acquisition of Nevro Corporation is seen as a strategic move to expand into a $3 billion market space, enhancing Globus Medical Inc (NYSE:GMED)'s reach in the musculoskeletal market.

This revision was influenced by the earlier-than-expected closure of the Nevro acquisition. Analysts from BTIG and Stifel responded by lowering their price targets for the company to $77 and $70 ...

Before that, as Regional Director at Nevro, he doubled division revenue and contributed to the successful U.S. launch of the HF10 therapy. Earlier in his career, Mr. Thiyagalingam held senior ...

Before that, as Regional Director at Nevro, he doubled division revenue and contributed to the successful U.S. launch of the HF10 therapy. Earlier in his career, Mr. Thiyagalingam held senior ...

BA stock traded up $2.60 during trading on Friday, reaching $185.49. The company’s stock had a trading volume of 8,681,274 shares, compared to its average volume of 9,062,111. The company has a ...

BTIG analyst Ryan Zimmerman lowered the firm’s price target on Globus Medical (GMED) to $77 from $88 and keeps a Buy rating on the shares. The company’s Q1 results fell short of expectations ...

Devices featuring AI technology such as Nevro’s spinal cord stimulators which directly target the source of nerve pain and help restore physical and emotional well-being, are now widely in use ...

Miksic also asked about the opportunities the acquisition of Nevro Corporation will provide. Pfeil said that over time they plan to increase Nevro’s gross margins, but for right now they are focusing ...